# Protocol 3 — Opioid-Inclusive General Anesthesia (No Regional Blocks)

### Post-Mastectomy Breast Implant Revision

**Third-Line Pathway: Reserved for Specific Indications** • Version 2.0 — December 2025

[![License: CC BY 4.0](https://img.shields.io/badge/License-CC%20BY%204.0-lightgrey.svg)](https://creativecommons.org/licenses/by/4.0/)

---

## Educational Use Disclaimer

**This protocol is an educational framework, not an institutional clinical guideline.**

- Developed for pre-medical educational purposes and medical school application portfolio
- NOT approved for clinical use without institutional review and attending physician oversight
- All clinical decisions require attending anesthesiologist judgment and patient-specific assessment
- Does not replace formal anesthesia training, credentialing, or institutional policies
- Author is pre-medical student; content reflects literature synthesis, not clinical expertise

**For clinical implementation:** This framework requires validation by board-certified anesthesiologists, institutional governance review, pharmacy approval, and integration with local policies. No protocol substitutes for individualized patient assessment and attending-level clinical judgment.

---

## Protocol Hierarchy and Selection

### Protocol 3 is THIRD-LINE (Reserved for Specific Indications)

**Protocol Selection Hierarchy:**

1. **First-line:** Protocol 1 (OFIA + PECS blocks) - Best outcomes, lowest complications
2. **Second-line:** Protocol 2 (OFIA no blocks) - When blocks contraindicated/refused
3. **Third-line:** Protocol 3 (Opioid-inclusive) - ONLY when Protocols 1-2 inappropriate

**Protocol 3 should be the EXCEPTION, not routine practice.**

---

## When to Use Protocol 3

### Appropriate Indications (Narrow and Specific)

**Use Protocol 3 ONLY when:**

**Patient Factors:**
- Chronic opioid therapy with high tolerance (>50 MME/day baseline for ≥3 months)
- Multiple contraindications to OFIA adjuncts (dexmedetomidine, ketamine, lidocaine all contraindicated)
- Patient explicitly refuses opioid-sparing approach after informed discussion and counseling
- Severe anxiety/psychiatric condition requiring deeper opioid-supported sedation (rare; attending judgment)

**Clinical Factors:**
- Extremely painful procedure anticipated (extensive capsulectomy, total ADM reconstruction, infection washout)
- Previous Protocol 1 or 2 trial with inadequate analgesia in same patient
- Attending judgment that opioid approach safer for specific patient phenotype

**Important Principle:**
> Even when using Protocol 3, employ opioid minimization strategies:
> - Lowest effective opioid dose
> - Avoid late-case stacking
> - Multimodal non-opioid adjuncts
> - Enhanced safety monitoring

---

## Indications and Contraindications

### Indications (Specific)

| Indication | Rationale |
|------------|-----------|
| **Chronic opioid therapy** | Tolerance to opioid-sparing strategies; may require opioid-inclusive approach |
| **Multiple OFIA contraindications** | When dex, ketamine, lidocaine all contraindicated/ineffective |
| **Patient refusal of Protocols 1-2** | Autonomy; patient explicitly wants "traditional" anesthesia |
| **Previous Protocol 1-2 failure** | Inadequate analgesia despite optimization in same patient |

### Contraindications (Relative - Risk-Benefit Assessment)

| Consideration | Management Strategy |
|---------------|---------------------|
| **Very high PONV risk (Apfel 4)** | **Strongly reconsider Protocol 1 or 2**; if must use Protocol 3, aggressive prophylaxis mandatory |
| **Severe untreated OSA** | **Minimize opioids**; consider Protocol 2 with enhanced monitoring instead |
| **Elderly (>75) and frail** | Reduce opioid doses significantly; enhanced monitoring; consider Protocol 2 |
| **Opioid use disorder in recovery** | **Strongly prefer Protocol 1 or 2** to avoid opioid exposure |
| **Poorly controlled GERD** | Prefer ETT over LMA; rapid sequence if indicated |

**Key Point:** If patient has relative contraindications, reconsider whether Protocol 1 or 2 is actually safer option.

---

## Required Equipment and Preparation

### Monitoring Equipment

**Standard ASA Monitors:**
- Continuous ECG
- Pulse oximetry
- Non-invasive blood pressure (cycle q3-5 min)
- Capnography (continuous during intubation)
- Temperature monitoring
- Inspired/expired gas analysis

**Enhanced Monitoring (Consider):**
- Processed EEG (BIS, Entropy) - especially elderly, OSA, or tight depth control desired
- Arterial line only if severe cardiac disease

### Safety Equipment (MANDATORY for Protocol 3)

**Naloxone Preparation:**
- Naloxone 0.4 mg diluted in 10 mL NS (= 0.04 mg/mL) **at bedside in PACU**
- Immediately accessible, not locked in medication cabinet
- PACU staff familiar with dilution and titration protocol

**Airway Equipment:**
- Video laryngoscope preferred
- Endotracheal tubes (ETT preferred over LMA for Protocol 3)
- Full difficult airway cart available

---

## Preoperative Preparation

### Multimodal Oral Premedication (Given 1-2 Hours Preoperatively)

| Medication | Dose | Indications | Contraindications |
|------------|------|-------------|-------------------|
| **Acetaminophen** | 1000 mg PO | **ALL patients** (foundational multimodal) | Severe hepatic impairment |
| **Celecoxib** | 200-400 mg PO | If no renal/GI contraindications | CKD stage 4-5, active PUD, ASA allergy |
| **Gabapentin** | **NOT routinely recommended** | Consider ONLY if neuropathic pain AND age <65 | Age >75, cognitive impairment, OSA |

**Gabapentin Note:**
- Modern ERAS guidelines do NOT recommend routine gabapentinoids
- If used: **300 mg maximum** (lower end only)
- **Avoid in elderly, OSA, delirium-risk patients**
- Sedation and delirium risk outweigh modest analgesic benefit

### Anxiolysis (Conservative Approach)

| Medication | Dose | Notes |
|------------|------|-------|
| **Midazolam** | 1-2 mg IV | Use **minimum effective dose** |
| | | Avoid in elderly (≤0.5-1 mg) and OSA |
| | | Higher doses increase respiratory depression risk with opioids |

**Important:** Protocol 3 already has respiratory depression risk from opioids. Minimize additive sedatives.

### Antibiotic Prophylaxis

| Weight | Medication | Timing |
|--------|------------|--------|
| **<120 kg** | Cefazolin 2 g IV | 30-60 min before incision |
| **≥120 kg** | Cefazolin 3 g IV | 30-60 min before incision |
| **β-lactam allergy** | Vancomycin 15 mg/kg IV (max 2 g) | 60-120 min before incision |

**Re-dosing:**
- Cefazolin: q4h if case >4 hours
- Vancomycin: q12h (rarely needed for breast surgery)

### PONV Prophylaxis (MANDATORY and AGGRESSIVE)

**Protocol 3 has highest PONV risk - aggressive prophylaxis essential.**

**Minimum TWO agents; THREE if Apfel ≥3:**

| Apfel Score | Prophylaxis Strategy |
|-------------|---------------------|
| **2** | Dexamethasone 4-8 mg IV + Ondansetron 4 mg IV before emergence |
| **3** | Dexamethasone 8 mg IV + Ondansetron 4 mg IV + Scopolamine patch |
| **4** | Dexamethasone 8 mg IV + Ondansetron 4 mg IV + Scopolamine patch + **Strongly reconsider Protocol 1 or 2** |

**Additional PONV Reduction Strategies:**
- **Avoid nitrous oxide** (if used in your institution)
- Propofol TIVA preferred over volatile if very high PONV risk
- Minimize opioid total dose (use lowest effective)
- Adequate hydration (avoid hypovolemia)

**Expected PONV Rate:**
- With aggressive prophylaxis: 15-25%
- Without adequate prophylaxis: 25-40%

---

## Induction of General Anesthesia

### Pre-Induction Setup

**Patient Positioning:**
- Supine, arms tucked or on armboards
- Pressure point padding

**Monitoring:**
- Standard ASA monitors connected and functioning
- Baseline vital signs documented

**Pre-Oxygenation:**
- 100% O₂ for 3-5 minutes
- Target end-tidal O₂ >90%

### Induction Sequence (Opioid-Based)

| Step | Agent | Dose | Purpose | Notes |
|------|-------|------|---------|-------|
| **1** | **Fentanyl** | **1-1.5 mcg/kg IV** | Analgesia, hemodynamic blunting | **Reduce in elderly/OSA (see phenotypes below)** |
| **2** | **Lidocaine** | 1-1.5 mg/kg IV (max 100 mg) | Attenuate airway response | Optional; may omit in heart block |
| **3** | **Propofol** | 1.5-2 mg/kg IV | Induction of unconsciousness | **Reduce to 1-1.5 mg/kg if age >70, frail, ASA III-IV** |
| **4** | **Rocuronium** | 0.6-1 mg/kg IV | Neuromuscular blockade | Or succinylcholine 1-1.5 mg/kg if RSI |

### Fentanyl Dosing by Phenotype (CRITICAL)

| Patient Phenotype | Fentanyl Induction Dose | Rationale |
|-------------------|------------------------|-----------|
| **Healthy adult (ASA I-II, age <65)** | 1-1.5 mcg/kg | Standard dosing |
| **Elderly (age >70)** | **0.5-1 mcg/kg** | Increased sensitivity, reduced clearance |
| **Frail or ASA III-IV** | **0.5-1 mcg/kg** | Hemodynamic instability risk |
| **OSA (any severity)** | **0.5-1 mcg/kg** | Respiratory depression risk |
| **Opioid-naïve** | **1 mcg/kg** | Lower end of range |
| **Chronic opioid use** | **1.5-2 mcg/kg** | Tolerance; may need higher dose |

**Important:** These are INDUCTION doses only. Additional intraoperative opioids managed separately (see Maintenance section).

### Airway Management

**Endotracheal Intubation (STRONGLY PREFERRED for Protocol 3):**
- Video laryngoscopy preferred
- ETT size: 7.0-7.5 mm (women), 7.5-8.0 mm (men)
- Cuff pressure 20-30 cm H₂O

**Why ETT Preferred Over LMA:**
- Better airway protection (GERD risk with opioids)
- More secure if high opioid doses needed
- Easier ventilation management
- Lower aspiration risk

**Supraglottic Airway (LMA):**
- Acceptable if short case, low aspiration risk, healthy patient
- NOT recommended if OSA, obesity, GERD

**Confirm Placement:**
- End-tidal CO₂ waveform
- Bilateral breath sounds
- Chest rise

---

## Maintenance of Anesthesia

### Hypnotic Agent (Choose ONE)

**Option A: Propofol TIVA**
- 75-150 mcg/kg/min (4.5-9 mg/kg/hr)
- Elderly/frail: 50-100 mcg/kg/min
- **Preferred if Apfel ≥3** (PONV reduction)
- Target BIS 40-60 if processed EEG used

**Option B: Volatile Anesthetic (Sevoflurane/Desflurane)**
- Sevoflurane: 1.5-2.5% end-tidal (0.8-1.2 MAC age-adjusted)
- Desflurane: 4-6% end-tidal
- Acceptable alternative; propofol preferred for PONV prophylaxis

### Intraoperative Opioid Strategy (CRITICAL SAFETY SECTION)

**Principle:** Use LOWEST EFFECTIVE DOSE to minimize respiratory depression and PONV while maintaining adequate analgesia.

**Choose ONE Approach:**

#### Option A: Low-Rate Fentanyl Infusion (PREFERRED - More Predictable)

**Dosing:**
- 0.5-1 mcg/kg/hr infusion
- Adjust based on surgical stimulus and hemodynamics
- **STOP 20-30 minutes before anticipated end of case**

**Advantages:**
- Steady-state analgesia
- Less risk of accidental stacking
- Easier to taper before emergence

**Monitoring:**
- Ensure infusion stopped on time (set alarm)
- Adjust rate if hemodynamic instability or movement

#### Option B: Intermittent Bolus Dosing (Requires Discipline)

**Dosing:**
- Fentanyl 25-50 mcg IV increments as needed for surgical stimulus
- **CRITICAL:** **Avoid boluses in final 20-30 minutes of case**
- Total cumulative dose typically 100-200 mcg for 1-2 hour case

**Advantages:**
- Familiar to most practitioners
- Can titrate to specific stimuli

**Disadvantages:**
- **High risk of late stacking** if not disciplined
- Easy to lose track of total dose
- Must consciously avoid dosing near end

**Safety Rule:** Set timer or mark chart "No fentanyl after [time]" to prevent late dosing.

### End-of-Case Analgesia (Long-Acting Opioid)

**If case >1 hour or moderate-high pain anticipated:**

**Hydromorphone:**
- 0.2-0.4 mg IV in small increments
- **NOT within 15 minutes of planned extubation**
- Provides 3-4 hours of analgesia for PACU period

**Phenotype Adjustments:**
- **Opioid-naïve/elderly/frail/OSA:** 0.2 mg IV, reassess ≥20 minutes
- **Standard adult:** 0.2-0.4 mg IV
- **Chronic opioid use:** 0.4-0.8 mg IV (tolerance expected)

**Critical Timing:**
- Give EARLY in case (at least 20-30 min before extubation planned)
- Allows assessment of respiratory effect before emergence
- If given too late → delayed emergence, respiratory depression

### Surgeon Local Infiltration (STRONGLY ENCOURAGED)

**Even in opioid-based protocol, surgeon infiltration reduces total opioid needs.**

**Recommended:**
- Bupivacaine 0.25% or ropivacaine 0.2-0.375%
- Volume: 20-30 mL total
- Infiltrate: subcutaneous tissues, pocket, around drains
- Timing: before incision, during dissection, before closure

**Coordinate with anesthesia team:**
- Document agent, concentration, volume
- Account for total local anesthetic dose if using systemic lidocaine

### Multimodal Adjuncts (Optional - Reduce Opioid Needs)

**Even in Protocol 3, multimodal agents can reduce total opioid requirement:**

**Consider:**
- Dexmedetomidine 0.2-0.4 mcg/kg/hr (if no contraindications)
- Ketamine 0.2-0.3 mg/kg induction bolus (if no contraindications)
- IV lidocaine 1-1.5 mg/kg/hr (if no contraindications)

**Why Optional:**
- Protocol 3 patients often have contraindications to these agents
- If OFIA adjuncts were appropriate, should use Protocol 1 or 2 instead
- Use selectively when can safely reduce opioid burden

### Ventilation Strategy

**Lung-Protective Ventilation:**

| Parameter | Target |
|-----------|--------|
| **Tidal Volume** | 6-8 mL/kg ideal body weight |
| **Respiratory Rate** | 10-14 breaths/min |
| **PEEP** | 5-8 cm H₂O |
| **FiO₂** | 0.4-0.5 (target SpO₂ >94%) |
| **EtCO₂** | 35-40 mmHg |

---

## Intraoperative Management

### Hemodynamic Goals

| Parameter | Target Range | Management |
|-----------|--------------|------------|
| **MAP** | 65-90 mmHg (or ±20% baseline) | Phenylephrine 50-100 mcg IV for hypotension |
| **Heart Rate** | 50-90 bpm | Usually stable with opioid-based technique |
| **SpO₂** | ≥94% | Increase FiO₂, check ventilator |

**Hypotension Management:**
- Opioids can cause vasodilation → phenylephrine first-line
- If bradycardic: ephedrine 5-10 mg IV
- Ensure adequate fluid status
- Reduce volatile agent if excessive

**Hypertension Management:**
- Usually indicates inadequate depth or analgesia
- Increase hypnotic (propofol or volatile)
- Consider additional fentanyl 25-50 mcg (if NOT near end of case)
- Rule out bladder distention, surgical stimulus

### Fluid Management

**Goal-Directed, Restrictive:**
- 2-4 mL/kg/hr crystalloid maintenance
- Replace estimated blood loss 1:1
- **Goal: <1500 mL total for 1-2 hour case**
- Avoid fluid overload (worsens PONV, edema)

### Temperature Management

**Maintain Normothermia:**
- Forced air warming blanket
- Warmed IV fluids if large volume
- Target core temperature >36°C

---

## Emergence and Extubation

### Emergence Protocol (~10-15 Minutes Before Anticipated End)

**Taper Plan:**

| Agent | Taper Strategy |
|-------|----------------|
| **Fentanyl infusion** | **STOP 20-30 minutes before end** (critical safety point) |
| **Hydromorphone** | Should already be given ≥20 min before end; no additional doses |
| **Propofol/Volatile** | Taper for awakening; target BIS 70-80 for emergence |
| **Adjuncts (if used)** | Stop dexmedetomidine 10-15 min before end |

**Antiemetic Administration:**
- Ondansetron 4 mg IV before emergence (if not already given)
- Have rescue antiemetics ready (metoclopramide, promethazine)

**Neuromuscular Blockade Reversal:**
- **Sugammadex 2-4 mg/kg IV** (preferred for Protocol 3)
  - 2 mg/kg if TOF 2-4 twitches
  - 4 mg/kg if TOF 0-1 twitch or deep block
- **OR Neostigmine 0.04-0.07 mg/kg + Glycopyrrolate 0.01 mg/kg**
  - Only if TOF ≥2 twitches
  - Max neostigmine 5 mg

**Sugammadex Preferred for Protocol 3:**
- More reliable reversal
- Faster extubation
- Reduces residual weakness risk

### Extubation Criteria (ENHANCED for Protocol 3)

**Protocol 3 requires HIGHER bar for extubation due to opioid respiratory depression risk:**

| Criterion | Standard (P1-2) | **Enhanced (P3)** |
|-----------|----------------|-------------------|
| **Consciousness** | Following commands | **FULLY AWAKE**, conversing appropriately |
| **Ventilation** | Adequate RR and TV | **Robust ventilation** (RR 10-20, strong effort) |
| **Oxygenation** | SpO₂ >92% | SpO₂ >94% on minimal O₂ |
| **Sedation** | Arousable | **Minimal somnolence** (RASS 0 to -1 maximum) |
| **NMB Reversal** | TOF >0.9 | TOF >0.9, sustained head lift >5 sec |

**Do NOT Extubate If:**
- Somnolent (RASS ≤-2) - **HIGH RISK with opioids**
- Inadequate ventilation (weak respiratory effort, low TV)
- Hemodynamically unstable
- Residual neuromuscular blockade

**Lower Threshold to Delay Extubation:**
- If ANY concern about respiratory drive
- OSA patients - must be FULLY awake
- Elderly with high opioid exposure
- Better to delay 10-15 minutes than extubate prematurely

**Post-Extubation:**
- 100% O₂ by face mask initially
- **Continuous monitoring** - opioid-related respiratory depression can occur post-extubation
- Encourage deep breathing
- Position head-up 30-45°

---

## PACU Management

### Expected Clinical Course (Protocol 3)

**Typical Early Course:**
- **Pain initially LOW** (residual intraoperative opioids)
- **Pain REBOUNDS** at 2-4 hours as opioids wear off
- **PONV risk HIGH** (15-25% despite prophylaxis)
- **Sedation risk** (especially elderly, OSA)
- **Respiratory depression risk** (monitor closely)
- **Longer PACU stay** (120-180 minutes typical)

**Key Point:** Early comfort does NOT mean good analgesia plan - anticipate rebound pain.

---

## Expected Clinical Outcomes (Protocol 3)

| Metric | Protocol 3 Target | Comparison |
|--------|-------------------|------------|
| **PACU Pain (NRS)** | **Initially 2-4/10, then rebounds to 5-8/10** at 2-4 hours | P1: 1-3/10; P2: 3-6/10 |
| **PONV Incidence** | **15-25%** (with aggressive prophylaxis) | P1: 3-8%; P2: 10-15% |
| **Respiratory Events** | **5-10%** (desaturation, oversedation) | P1-2: <2% |
| **Naloxone Use** | **1-3%** | P1-2: <0.5% |
| **Time to Discharge** | **120-180 min** | P1: 60-90; P2: 90-120 |
| **Patient Satisfaction** | **Lower** (more side effects) | P1-2: Higher satisfaction |

**Key Point:** Protocol 3 has highest complication rates and longest recovery. Enhanced monitoring and safety protocols MANDATORY. This is why Protocol 3 is third-line.

---

### PACU Monitoring Requirements (ENHANCED for Protocol 3)

**Protocol 3 requires MORE intensive monitoring than Protocols 1-2:**

| Parameter | Frequency | Duration | Notes |
|-----------|-----------|----------|-------|
| **Vital Signs** | **Q10-15 min initially** (vs q15 for P1-2) | Until fully stable | Closer monitoring due to opioid effects |
| **Pulse Oximetry** | **Continuous until FULLY ALERT** | Until RASS 0 and stable | **MANDATORY for Protocol 3** |
| **RASS Score** | **Q10-15 min** | First hour minimum | Sedation monitoring critical |
| **Pain Score (NRS)** | Q15 min | Until discharge | Anticipate rebound pain |
| **Respiratory Rate** | Q10-15 min | Until fully alert | Watch for hypoventilation |

**Enhanced Monitoring - Strongly Consider Capnography If:**
- OSA (diagnosed or STOP-BANG ≥3)
- Elderly (>70 years)
- Opioid-naïve patient
- High total opioid exposure (>200 mcg fentanyl equivalent + hydromorphone)
- Any episode of desaturation (SpO₂ <90%) or apnea
- Oversedation (RASS ≤-2)

**Capnography Monitoring:**
- End-tidal CO₂ continuous display
- Alert if EtCO₂ >50 mmHg or respiratory rate <8
- Early warning of hypoventilation before desaturation

---

### Pain Management (Multimodal Foundation)

**Scheduled Non-Opioid Analgesics (START IMMEDIATELY):**

| Medication | Dose | Frequency | Notes |
|------------|------|-----------|-------|
| **Acetaminophen** | 1000 mg PO/IV | Q6h scheduled | If not given preop; essential foundation |
| **Ketorolac** | 15 mg IV | Q6h × 48 hours | **First-line NSAID if no contraindications** |
| **OR Celecoxib** | 200 mg PO | Q12h | Alternative if ketorolac contraindicated |
| **OR Ibuprofen** | 400-600 mg PO | Q6h | Oral NSAID alternative |

**Contraindications to NSAIDs:**
- CKD stage 4-5 (eGFR <30)
- Active peptic ulcer disease
- Recent GI bleeding
- ASA/NSAID allergy
- Severe hepatic dysfunction
- Bleeding diathesis

**Additional Comfort Measures:**
- Ice packs to surgical site
- Head-up positioning
- Calm, quiet environment

---

### PACU Opioid Rescue (Phenotype-Specific and Conservative)

**Despite intraoperative opioids, breakthrough pain common at 2-4 hours.**

**Rescue Strategy:**
- Start with multimodal non-opioid foundation
- Use LOWEST effective opioid dose
- LONGER intervals than Protocols 1-2 (respiratory safety)
- Enhanced monitoring with opioid rescue

| Patient Phenotype | Hydromorphone Dose | Interval | Monitoring |
|-------------------|-------------------|----------|------------|
| **Opioid-naïve** | **0.2 mg IV** | **Q20-30 min** | **Continuous SpO₂ MANDATORY** |
| **Elderly (>70)** | **0.2 mg IV** | **Q25-30 min** | **Continuous SpO₂ + consider capnography** |
| **Frail or ASA III-IV** | **0.2 mg IV** | **Q25-30 min** | **Enhanced monitoring** |
| **OSA (any severity)** | **0.2 mg IV** | **Q30 min** | **Capnography STRONGLY RECOMMENDED** |
| **Standard adult** | 0.2-0.4 mg IV | Q15-20 min | Continuous SpO₂ until stable |
| **Chronic opioid use** | 0.4-0.8 mg IV | Q15-20 min | Tolerance expected; higher needs anticipated |

**Critical Safety Points:**
- **NEVER stack doses** - wait full interval before redosing
- **Reassess sedation** before each dose (check RASS score)
- **If RASS ≤-2:** HOLD opioids, increase monitoring
- **If desaturation:** HOLD opioids, stimulate, supplemental O₂

**Oral Opioid Transition (When Tolerating PO):**
- Oxycodone 5-10 mg PO q4-6h PRN
- Typically start once patient drinking liquids
- Continue multimodal non-opioid foundation

---

### Naloxone Protocol (MANDATORY Preparation)

**Indications for Naloxone Administration:**

| Severity | Clinical Signs | Naloxone Indication |
|----------|---------------|---------------------|
| **Mild** | RR 8-10, arousable, SpO₂ >90% | Observe closely, stimulate, DO NOT give naloxone yet |
| **Moderate** | RR <8, difficult to arouse, SpO₂ 85-90% | **GIVE NALOXONE** |
| **Severe** | Apnea, unarousable (RASS -4 to -5), SpO₂ <85% | **GIVE NALOXONE + call for help** |

**Naloxone Dosing Protocol:**

**Preparation:**
- Naloxone 0.4 mg diluted in 10 mL NS = **0.04 mg/mL**
- Draw up BEFORE needed (at PACU admission for Protocol 3 patients)

**Administration:**
1. **Initial dose:** 0.04-0.08 mg IV (1-2 mL of diluted solution)
2. **Reassess:** Wait 2-3 minutes
3. **Goal:** Adequate ventilation (RR >10), arousable to voice, SpO₂ >92%
4. **NOT full reversal** - avoid precipitating severe pain
5. **Repeat:** If inadequate response, give additional 0.04-0.08 mg q2-3 min
6. **Maximum:** Usually 0.4 mg total sufficient

**After Naloxone:**
- **Extended monitoring MANDATORY** (naloxone half-life shorter than opioids)
- Watch for re-sedation at 30-60 minutes
- May need naloxone infusion if recurrent (0.04 mg/hr)
- Pain will return - have multimodal rescue ready
- **Escalate to monitored bed** (see criteria below)

---

### When to Escalate to Monitored Bed

**Consider Monitored Bed (Step-Down or ICU) If:**
- Naloxone required (any dose)
- Recurrent desaturation episodes (SpO₂ <90% more than once)
- Persistent oversedation (RASS ≤-2 for >30 minutes despite stimulation)
- OSA + high opioid exposure (>200 mcg fentanyl equivalent + hydromorphone)
- Respiratory rate <8 at any point
- EtCO₂ >50 mmHg persistently on capnography

**Mandatory Monitored Bed If:**
- **Naloxone administered**
- **Apneic episode** requiring intervention
- **Respiratory rate <8** at any point
- **Persistent desaturation** despite O₂ and interventions
- **Unarousable** (RASS -4 to -5)

**Monitored Bed Orders:**
- Continuous pulse oximetry with telemetry
- Capnography monitoring
- Vital signs q15 min minimum
- Naloxone at bedside
- Attending anesthesiologist and hospitalist notified

---

### PONV Management (Stepwise Rescue)

**Despite prophylaxis, PONV occurs in 15-25% of Protocol 3 patients.**

**Rescue Algorithm (Avoid Repeating Same Class):**

| Episode | Treatment | Dose | Notes |
|---------|-----------|------|-------|
| **First** | Ondansetron | 4 mg IV | If not already given; wait 15-20 min |
| **Second** | Metoclopramide | 10 mg IV | Avoid if recent dopamine antagonist |
| **Third** | Promethazine | 6.25-12.5 mg IV | Sedating; use cautiously |
| **Refractory** | Haloperidol | 0.5-1 mg IV | Off-label; very effective |

**Non-Pharmacologic:**
- Minimize movement
- Cool cloth to forehead
- Deep breathing exercises
- Avoid oral intake until nausea resolves

**If Severe/Refractory PONV:**
- Attending evaluation
- Consider longer PACU stay
- May need antiemetic infusion (ondansetron 1 mg/hr)
- Risk factor for hospital admission

---

### Discharge Readiness Criteria

**Modified Aldrete Score ≥9:**

| Criterion | Score |
|-----------|-------|
| **Activity** | Moves 4 extremities = 2; Moves 2 extremities = 1; No movement = 0 |
| **Respiration** | Deep breathing, coughing = 2; Dyspnea, shallow = 1; Apnea = 0 |
| **Circulation** | BP ±20 mmHg baseline = 2; BP ±20–50 mmHg = 1; BP ±>50 mmHg = 0 |
| **Consciousness** | Fully awake = 2; Arousable = 1; Not responding = 0 |
| **O₂ Saturation** | SpO₂ >92% room air = 2; SpO₂ >90% with O₂ = 1; SpO₂ <90% with O₂ = 0 |

**Additional Discharge Criteria (Protocol 3 Specific):**
- **Fully alert** (RASS 0) - higher bar than Protocols 1-2
- Pain controlled (NRS ≤4) with plan in place
- No active PONV or controlled with medications
- Surgical site stable (no hematoma, excessive bleeding)
- Vital signs stable for ≥30 minutes
- **No desaturation episodes in last 30 minutes**
- **Adequate spontaneous ventilation without stimulation**

**Do NOT Discharge If:**
- RASS ≤-1 (any somnolence)
- Recurrent desaturation
- Naloxone required (automatic monitored bed)
- Uncontrolled pain (NRS >6)
- Persistent PONV
- Hemodynamic instability
- Respiratory rate <10 or >24

**Protocol 3 patients typically require 120-180 minutes PACU time** (longer than P1-2).

---

## Postoperative Analgesia Plan (Home)

### Expected Home Course

**Pain Pattern:**
- Days 1-2: Moderate pain (NRS 4-6) as PACU opioids wear off
- Days 3-5: Improving (NRS 2-4)
- Week 2+: Minimal (NRS 0-2)

**PONV Risk:**
- Higher in first 24 hours
- Prescribe rescue antiemetics

### Scheduled Medications (48-72 Hours)

| Medication | Dose | Frequency | Duration | Notes |
|------------|------|-----------|----------|-------|
| **Acetaminophen** | 1000 mg PO | q6h scheduled | 48-72 hours | Do NOT exceed 4000 mg/day |
| **Ibuprofen** | 400-600 mg PO | q6h scheduled | 48-72 hours | With food; stop if GI upset |
| **OR Celecoxib** | 200 mg PO | q12h scheduled | 48-72 hours | Alternative if ibuprofen not tolerated |

**Important:** Even with opioid prescription, maintain scheduled non-opioid foundation.

### Opioid Prescription (Expected Need for Protocol 3)

**Unlike Protocols 1-2, opioid prescription typically NEEDED for Protocol 3 patients.**

**Standard Prescription:**
- **Oxycodone 5 mg tablets**
- **Quantity:** 15-20 tablets (#15-20)
- **Directions:** Take 1-2 tablets PO q4-6h PRN severe pain
- **Duration:** 3-5 days typically sufficient

**Phenotype Adjustments:**

| Patient Type | Prescription | Notes |
|--------------|-------------|-------|
| **Opioid-naïve, elderly** | Oxycodone 5 mg #10-15 | Lower quantity, shorter duration |
| **Standard adult** | Oxycodone 5 mg #15-20 | Standard prescription |
| **Chronic opioid use** | **Continue home regimen** + breakthrough | Coordinate with pain management/PCP |

**Chronic Opioid Patients:**
- Resume home long-acting opioid immediately postop
- Prescribe SHORT-acting for breakthrough (above baseline)
- Do NOT discontinue chronic therapy
- Coordinate with prescribing provider

### Opioid Safety Counseling (MANDATORY)

**Must discuss with patient:**
- **Risks:** Respiratory depression, constipation, nausea, addiction potential
- **Storage:** Secure location, away from children and others
- **Disposal:** Return unused pills to pharmacy or use disposal kit
- **Avoid:** Alcohol, benzodiazepines, driving while taking opioids
- **When to call:** Difficulty breathing, extreme drowsiness, confusion

**Document counseling** in discharge instructions.

### Antiemetic Prescription (If Apfel ≥2)

**Recommended:**
- Ondansetron 4 mg tablets #10-15
- Take 1 tablet q6-8h PRN nausea
- Especially important for Protocol 3 (higher PONV risk at home)

### When to Call Surgeon/Seek Care

**Call surgeon if:**
- Fever >101°F (38.3°C)
- Increasing redness, warmth, drainage at incision
- Uncontrolled pain despite medications
- Concerns about healing

**Seek emergency care if:**
- Difficulty breathing
- Chest pain
- Extreme drowsiness/confusion
- Signs of blood clot (leg swelling, chest pain, shortness of breath)

---

## Special Populations (Protocol 3 - Highest Risk)

### Elderly Patients (Age >70) - MAXIMUM RISK CATEGORY

**Why Elderly Are Highest Risk in Protocol 3:**
- Increased opioid sensitivity (3-4× more sensitive than young adults)
- Reduced clearance (longer half-lives)
- Higher delirium risk
- More comorbidities (cardiac, respiratory, renal)

**Required Modifications:**

**Preoperative:**
- **Avoid gabapentin completely** (delirium risk too high)
- Minimize midazolam (≤0.5-1 mg total)
- Enhanced delirium risk assessment

**Intraoperative:**
- **Fentanyl:** 0.5-1 mcg/kg induction (reduce 33-50%)
- **Propofol:** 1-1.5 mg/kg induction
- **Maintenance:** Reduce all agents 25-33%
- **Hydromorphone:** 0.2 mg IV maximum, ≥20 min before extubation

**PACU:**
- **Continuous SpO₂ MANDATORY**
- **RASS scoring q10 min** (delirium detection)
- **Hydromorphone rescue:** 0.2 mg IV, q25-30 min intervals ONLY
- **Enhanced monitoring** until RASS 0 for ≥30 minutes
- **Lower threshold for capnography**

**Discharge:**
- **Oxycodone 5 mg #10 maximum** (lower quantity)
- Enhanced family education on monitoring
- Consider next-day phone call follow-up

**Do NOT Discharge Elderly Protocol 3 Patients If:**
- Any somnolence (RASS <0)
- Confusion or disorientation
- Gait instability
- Inadequate home supervision

---

### Obstructive Sleep Apnea (OSA) - CRITICAL SAFETY POPULATION

**OSA + Opioids = DANGEROUS COMBINATION**

**Risk:** Opioids worsen upper airway obstruction and reduce central respiratory drive.

**Preoperative Assessment:**
- STOP-BANG score (≥3 = high risk, ≥5 = very high risk)
- Known OSA severity (mild/moderate/severe)
- CPAP compliance at home

**If OSA Diagnosed or STOP-BANG ≥3:**

**STRONGLY RECONSIDER Protocol 3 → Use Protocol 1 or 2 instead if at all possible**

**If Protocol 3 Must Be Used:**

**Intraoperative:**
- **Fentanyl:** 0.5-1 mcg/kg maximum induction
- **Minimize total opioid exposure** throughout case
- **Consider dexmedetomidine** 0.2-0.4 mcg/kg/hr (reduces opioid needs, less respiratory depression)
- **STOP fentanyl infusion 30 minutes before end** (earlier than standard)

**PACU:**
- **Continuous SpO₂ MANDATORY**
- **Capnography STRONGLY RECOMMENDED** (especially STOP-BANG ≥5)
- **Hydromorphone rescue:** 0.2 mg IV, **q30 min intervals ONLY**
- **Enhanced monitoring:** Do NOT reduce until patient RASS 0 and stable ≥60 min
- **Head-up positioning 30-45°** (improves upper airway patency)

**Discharge Criteria (Higher Bar):**
- **Must be FULLY ALERT** (RASS 0)
- **No desaturation episodes in last 60 minutes** (vs 30 min standard)
- **Stable on room air** (no supplemental O₂ requirement)
- **Patient has CPAP at home and will use it** (document)

**Consider Monitored Bed If:**
- STOP-BANG ≥5 (very high risk)
- Severe OSA (AHI >30)
- Total opioid exposure >150 mcg fentanyl equivalent
- Any desaturation episode in PACU

**Home Instructions:**
- **Use CPAP religiously** night of surgery and following nights
- **Sleep elevated** (head-of-bed 30-45°)
- **Minimize opioid use** (use scheduled NSAIDs/acetaminophen aggressively)
- **If opioids needed:** Take during day only (avoid at bedtime if possible)

---

### Chronic Opioid Use (>50 MME/day Baseline)

**This is the PRIMARY indication for Protocol 3.**

**Challenges:**
- Tolerance (higher intraoperative and PACU requirements)
- Opioid-induced hyperalgesia (paradoxically MORE pain)
- Risk of inadequate analgesia if undertreated
- Risk of withdrawal if baseline therapy interrupted

**Preoperative Assessment:**
- Document baseline opioid regimen (drug, dose, frequency, total MME/day)
- Last dose taken before surgery
- History of substance use disorder
- Current prescriber and pain management involvement

**Perioperative Management:**

**Preoperative:**
- **Continue baseline long-acting opioid** day of surgery (with small sip water)
- Do NOT hold chronic therapy (risk of withdrawal)

**Intraoperative:**
- **Higher opioid requirements expected:**
  - Fentanyl 1.5-2 mcg/kg induction
  - Fentanyl infusion 1-1.5 mcg/kg/hr OR boluses 50-100 mcg as needed
  - Hydromorphone 0.4-0.8 mg for longer-acting analgesia
- **Still apply safety principles** (avoid late stacking, monitor closely)

**PACU:**
- **Anticipate higher rescue needs** (this is NORMAL, not "drug-seeking")
- **Hydromorphone 0.4-0.8 mg IV q15-20 min** as needed
- **Resume baseline long-acting opioid ASAP** (critical to prevent withdrawal)
- **Multimodal foundation still essential** (acetaminophen, NSAIDs)

**Discharge:**
- **Resume home opioid regimen immediately**
- **Prescribe SHORT-acting opioid for breakthrough** (above baseline needs)
  - Example: If on oxycodone ER 40 mg q12h at home → continue this PLUS oxycodone IR 10 mg q4h PRN #20
- **Coordinate with chronic prescriber** (PCP, pain management)
- **Do NOT discontinue chronic therapy** (ethical and safety issue)

**Important Principle:**
> Patients on chronic opioids are NOT "abusing drugs" by needing more opioids perioperatively. Tolerance is physiologic. Treat pain adequately while coordinating with chronic prescriber.

---

### Opioid Use Disorder (OUD) in Recovery

**If patient is in recovery from OUD:**

**STRONGLY PREFER Protocol 1 or 2** to avoid opioid exposure that could trigger relapse.

**If Protocol 3 Must Be Used:**

**Preoperative Discussion (Critical):**
- **Informed consent** about opioid exposure
- **Relapse risk** discussion
- **Support system** activated (sponsor, counselor)
- **Plan for minimal opioid exposure**

**Perioperative:**
- **Minimize opioid dose** (use multimodal aggressively)
- **Short-acting opioids only** (avoid long-acting)
- **Taper rapidly** (1-3 days maximum)

**Discharge:**
- **Limit opioid prescription:** Oxycodone 5 mg #5-10 maximum
- **Close follow-up:** 24-48 hour phone call
- **Support system engaged:** Family/sponsor aware of opioid prescription
- **Early taper:** 2-3 days maximum opioid use

**Consider:**
- Buprenorphine patients: Coordinate with addiction medicine (continue buprenorphine perioperatively when possible)
- Methadone patients: Continue methadone, may need higher dose temporarily

---

## Key Safety Considerations

### Opioid-Related Respiratory Depression

**Highest Risk Period:** First 2-4 hours PACU

**Risk Factors:**
- Elderly (>70 years)
- OSA
- Opioid-naïve
- High total opioid exposure (>200 mcg fentanyl equivalent)
- Concurrent sedatives (benzodiazepines, gabapentin)
- Renal/hepatic impairment

**Early Recognition:**

| Severity | Clinical Signs | Action |
|----------|---------------|--------|
| **Mild** | RR 10-12, arousable, SpO₂ >92% | Observe, stimulate, reduce further opioids |
| **Moderate** | RR 8-10, difficult to arouse, SpO₂ 88-92% | Stimulate, supplemental O₂, hold opioids, frequent reassessment |
| **Severe** | RR <8, minimally responsive, SpO₂ <88% | **NALOXONE** + call for help |

**Prevention:**
- Phenotype-appropriate dosing
- Avoid late-case stacking
- Enhanced PACU monitoring
- Longer intervals between rescue doses
- Multimodal non-opioid foundation

---

### PONV (Postoperative Nausea and Vomiting)

**Protocol 3 Has Highest PONV Risk:**
- Opioids are highly emetogenic
- Even with aggressive prophylaxis, 15-25% incidence

**Prevention (Already Covered):**
- Minimum 2 agents prophylaxis (3 if Apfel ≥3)
- Propofol TIVA preferred over volatile
- Minimize opioid total dose
- Adequate hydration

**If PONV Occurs Despite Prophylaxis:**
- Follow stepwise rescue algorithm (avoid repeating classes)
- May need antiemetic infusion if severe
- Consider longer PACU observation
- Risk factor for hospital admission

**Severe PONV Complications:**
- Dehydration
- Electrolyte abnormalities
- Aspiration risk
- Wound dehiscence (rare, from forceful vomiting)
- Patient distress and dissatisfaction

---

### Delayed Emergence and Prolonged Sedation

**More Common in Protocol 3:**
- Residual opioid effect
- Synergy with benzodiazepines/gabapentin
- Elderly patients
- Hepatic/renal impairment

**Management:**
- **Time** (most important)
- **Stimulation** (verbal, tactile)
- **Rule out other causes:**
  - Hypoglycemia
  - Hypothermia
  - Residual neuromuscular blockade
  - Metabolic derangement

**Do NOT give naloxone** for simple prolonged sedation if ventilation adequate.

**If prolonged (>60-90 min):**
- Attending evaluation
- Consider monitored bed
- Check glucose, temperature
- TOF monitoring (rule out residual NMB)

---

### Hemodynamic Instability

**Opioids can cause:**
- Vasodilation → hypotension
- Bradycardia (high doses)

**Management:**
- Phenylephrine 50-100 mcg IV for hypotension
- Ephedrine 5-10 mg IV if bradycardic
- Fluid bolus if hypovolemic
- Reduce opioid infusion rate if excessive

**Hypertension/Tachycardia:**
- Usually indicates inadequate analgesia or depth
- Rule out bladder distention, surgical stimulus
- Treat pain appropriately

---

## Documentation Requirements

### Preoperative Note

**Required Elements:**
- Informed consent for opioid-inclusive anesthesia
- Rationale for Protocol 3 selection (why not Protocol 1 or 2)
- Baseline opioid use documented (if chronic therapy)
- OSA assessment (STOP-BANG score)
- Delirium risk assessment (if elderly)
- Apfel PONV score and prophylaxis plan
- Anesthesia plan: Protocol 3 with opioid minimization principles

### Intraoperative Record

**Document:**
- Induction agents and doses (fentanyl dose, propofol, rocuronium)
- Maintenance technique (volatile vs TIVA)
- **Total opioid exposure:**
  - Fentanyl total (mcg)
  - Hydromorphone total (mg)
  - Fentanyl equivalent calculation helpful
- Surgeon local infiltration (if performed)
- PONV prophylaxis agents
- Hemodynamic trends and interventions
- Emergence medications (reversal, antiemetics)
- Extubation time and condition

**Example:**
```text
Protocol 3 - Opioid-Inclusive GA
Induction: Fentanyl 100 mcg, Lidocaine 100 mg, Propofol 120 mg, Rocuronium 50 mg
Maintenance: Sevoflurane 1.5-2%, Fentanyl infusion 50 mcg/hr × 60 min (total 50 mcg)
Additional fentanyl boluses: 25 mcg × 2 = 50 mcg
Hydromorphone 0.4 mg IV at 45 min before end
TOTAL OPIOIDS: Fentanyl 200 mcg + Hydromorphone 0.4 mg
Surgeon infiltration: Bupivacaine 0.25% 20 mL
PONV prophylaxis: Dexamethasone 8 mg, Ondansetron 4 mg
Emergence: Smooth, extubated awake, transferred to PACU in stable condition
```


### PACU Handoff

**Critical Information:**
- **Protocol 3 used** (alerts PACU to enhanced monitoring needs)
- **Total opioid exposure** (fentanyl equivalent)
- **Timing of last opioid dose** (risk assessment for respiratory depression)
- **OSA status** (if applicable)
- **Elderly/frail status** (if applicable)
- **Chronic opioid use** (if applicable - expect higher rescue needs)
- **PONV prophylaxis given**
- **Pain on arrival** (NRS score)
- **Monitoring requirements:** Enhanced for Protocol 3
- **Naloxone availability** confirmed

**Example Handoff:**
```text
67F s/p L breast implant revision for capsular contracture
Protocol 3 - opioid-inclusive (patient refused blocks and OFA)
TOTAL OPIOIDS: Fentanyl 150 mcg + Hydromorphone 0.4 mg (last dose 25 min ago)
OSA (STOP-BANG 4) - enhanced monitoring, continuous SpO2, consider capnography
Pain on arrival: 3/10
PONV prophylaxis: Dex 8 mg, Ondansetron 4 mg
Naloxone at bedside ready
Anticipate: Rebound pain at 2-4 hours, monitor for respiratory depression
```

### Discharge Summary

**Document:**
- Protocol used (Protocol 3)
- Total PACU time
- Pain control achieved (NRS scores over time)
- Rescue medications required
- Complications (PONV, desaturation, naloxone use)
- Discharge medications (opioid prescription details)
- Opioid safety counseling provided
- Follow-up instructions

---

## Troubleshooting Common Scenarios

### Scenario 1: Inadequate Analgesia Despite High Opioid Doses

**Recognition:**
- Pain NRS >6 despite fentanyl 200+ mcg and hydromorphone
- Patient in distress
- Chronic opioid use or high tolerance suspected

**Management:**
1. **Verify no surgical complication** (hematoma, tight pocket)
2. **Optimize multimodal:**
   - Ensure acetaminophen and NSAIDs given
   - Ice packs, positioning
3. **Consider ketamine rescue:** 10-30 mg IV boluses if institutional protocol allows
4. **Higher opioid doses may be needed:**
   - Hydromorphone 0.8-1.2 mg IV total (chronic opioid patients)
   - Longer-acting oral opioids earlier (oxycodone 10 mg PO)
5. **Attending evaluation:** May need altered discharge plan
6. **For future cases:** Strongly recommend Protocol 1 for this patient

**Prevention:**
- Better patient selection (chronic opioid users may need Protocol 1 with blocks for adequate analgesia)

---

### Scenario 2: Respiratory Depression (RR <8, SpO₂ <90%)

**Recognition:**
- Respiratory rate <8
- SpO₂ <90% despite supplemental O₂
- Difficult to arouse (RASS -3 or worse)
- May have pinpoint pupils

**Immediate Management:**
1. **Call for help** (code team, attending anesthesiologist)
2. **Stimulate patient** (verbal, tactile, sternal rub)
3. **Airway support:**
   - Jaw thrust, head tilt-chin lift
   - 100% O₂ by face mask or bag-mask ventilation if needed
4. **GIVE NALOXONE:**
   - 0.04-0.08 mg IV (1-2 mL of diluted 0.04 mg/mL solution)
   - Reassess in 2-3 minutes
   - Repeat 0.04-0.08 mg q2-3 min until adequate ventilation
5. **Monitor closely:**
   - Continuous SpO₂ and capnography
   - Vital signs q5 min
   - Watch for re-sedation (naloxone half-life ~30-60 min, shorter than opioids)

**After Stabilization:**
- **Mandatory escalation to monitored bed**
- May need naloxone infusion (0.04-0.08 mg/hr)
- Extended monitoring (4-6 hours minimum)
- Pain management challenging (opioids reversed)
  - Use multimodal non-opioids
  - Low-dose ketamine if available
  - May need small opioid doses with very close monitoring

**Prevention:**
- Phenotype-appropriate dosing
- Avoid late-case stacking
- Enhanced PACU monitoring
- Identify high-risk patients (OSA, elderly, opioid-naïve)

---

### Scenario 3: Severe PONV Refractory to Multiple Agents

**Recognition:**
- Multiple vomiting episodes despite ondansetron, metoclopramide, promethazine
- Unable to tolerate oral intake
- Risk of dehydration

**Management:**
1. **Rule out surgical complication** (ileus unlikely in breast surgery, but consider)
2. **Additional rescue agents:**
   - Haloperidol 0.5-1 mg IV (very effective, off-label)
   - Dexamethasone 4 mg IV if not already given full dose
   - Scopolamine patch if not already placed
3. **Antiemetic infusion:**
   - Ondansetron 1 mg/hr continuous infusion
4. **Supportive care:**
   - IV fluids (lactated Ringer's 500-1000 mL bolus)
   - Cool compresses
   - Calm, dark, quiet environment
5. **Consider propofol rescue:** 10-20 mg IV (off-label, effective but sedating)

**If Refractory:**
- Attending evaluation
- **May require hospital admission** (23-hour observation or overnight)
- Continue antiemetic infusion and IV fluids
- Gradual advancement of diet

**Prevention:**
- Better patient selection (Apfel 4 patients should use Protocol 1 or 2 if possible)
- Aggressive prophylaxis (≥3 agents)

---

### Scenario 4: Patient Demands More Opioids ("Drug-Seeking Behavior")

**This is a challenging and sensitive scenario.**

**Important Principles:**
1. **Pain is subjective** - believe the patient
2. **Chronic opioid users have tolerance** - higher needs are physiologic, not "drug-seeking"
3. **Undertreated pain is unethical**
4. **Opioid use disorder is a medical condition** - treat with compassion

**Approach:**

**If Inadequate Pain Control:**
- Assess pain objectively (NRS score, function, distress)
- Optimize multimodal non-opioid foundation first
- If still inadequate, provide appropriate opioid rescue
- Do NOT withhold opioids from patients in genuine pain

**If Concern for Problematic Use:**
- Focus on function, not just pain score ("Can you take deep breaths? Move arms?")
- Set expectations ("We'll keep your pain manageable, goal NRS ≤4")
- Multimodal emphasis
- If prescribing opioids at discharge, consider:
  - Limited quantity
  - Close follow-up
  - Coordinate with PCP/pain management
  - Offer addiction resources if appropriate

**If Opioid Use Disorder Suspected:**
- Compassionate, non-judgmental approach
- Treat acute pain appropriately (OUD does not mean no opioids perioperatively)
- Offer resources (addiction medicine consult, peer support)
- Close follow-up critical

**Never:**
- Accuse patient of "drug-seeking"
- Withhold appropriate analgesia
- Use pejorative language in chart

---

## Quality Metrics and Outcomes

### Expected Outcomes Benchmarks (Institutional Review)

**Protocol 3 Performance Targets:**

| Metric | Target | Action if Not Met |
|--------|--------|-------------------|
| **PONV Incidence** | <25% | Review prophylaxis compliance; consider Protocol 1-2 for high-risk |
| **Respiratory Events** | <10% | Review dosing; enhance monitoring; patient selection |
| **Naloxone Use** | <3% | Review opioid dosing and timing; avoid late stacking |
| **Unplanned Admission** | <5% | Review patient selection and PACU management |
| **Patient Satisfaction** | >80% "satisfied" | Review pain control adequacy and PONV management |
| **PACU Time** | <180 min for 80% | Review emergence protocols and discharge criteria |

### Process Metrics to Track

**Monthly Review Recommended:**
- Number of Protocol 3 cases vs total breast cases (should be minority)
- Reasons Protocol 3 selected (ensure appropriate indications)
- Complications (PONV, respiratory depression, naloxone use)
- Unplanned admissions
- Patient complaints or concerns

**Quality Improvement Triggers:**
- Protocol 3 use >30% of cases → Education on Protocol 1-2 benefits
- PONV rate >30% → Review prophylaxis protocols
- Respiratory events >15% → Review dosing and monitoring
- Naloxone use >5% → Immediate review of opioid management

### Continuous Improvement

**Quarterly Case Review:**
- Aggregate outcome data
- Identify trends
- Adjust protocol if needed
- Share results with department

**Annual Protocol Review:**
- Update based on new evidence
- Incorporate lessons learned
- Benchmark against national data
- Consider sunset of Protocol 3 if Protocols 1-2 can cover most patients safely

---

## Evidence Base and References

### Key Guidelines

**1. ASA Practice Guidelines for Postoperative Pain Management (2023)**
- Multimodal analgesia recommended
- Opioid-sparing techniques when appropriate
- Enhanced monitoring for high-risk patients

**2. ERAS Society Guidelines: Breast Surgery (2023-2024)**
- Regional anesthesia preferred when feasible
- Minimize opioids while ensuring adequate analgesia
- Aggressive PONV prophylaxis

**3. ASRA Pain Management Guidelines (2023)**
- Balanced approach to opioid use
- Chronic opioid patients require individualized plans
- Monitor for respiratory depression

### Supporting Literature

**Opioid-Related Respiratory Depression:**
- Incidence 1-5% in PACU depending on definition
- Risk factors: OSA, elderly, opioid-naïve, high doses
- Continuous monitoring reduces adverse events

**PONV in Opioid-Based Anesthesia:**
- Baseline incidence 20-40% without prophylaxis
- Aggressive multi-agent prophylaxis reduces to 15-25%
- Patient satisfaction strongly correlated with PONV control

**Naloxone Titration:**
- Dilute dosing (0.04-0.08 mg increments) preferred over full reversal
- Avoids precipitating severe pain
- Reduces hemodynamic instability

---

## Appendices

### Appendix A: Opioid Equivalency Calculator

**For Reference (Rescue Dosing):**

| Opioid | Route | Dose | Morphine Equivalent |
|--------|-------|------|---------------------|
| **Morphine** | IV | 10 mg | 10 mg (1.0×) |
| **Hydromorphone** | IV | 1.5 mg | 10 mg (6.7×) |
| **Fentanyl** | IV | 100 mcg | 10 mg (0.1×) |
| **Oxycodone** | PO | 15 mg | 10 mg (0.67×) |

**Example Calculation:**
- Fentanyl 200 mcg + Hydromorphone 0.4 mg =
- (200 mcg × 0.1) + (0.4 mg × 6.7) =
- 20 mg + 2.7 mg = **22.7 mg morphine equivalents**

### Appendix B: STOP-BANG Questionnaire

**OSA Screening Tool:**

| Question | Yes = 1 point |
|----------|---------------|
| **S**noring: Do you snore loudly? | |
| **T**ired: Do you often feel tired during the day? | |
| **O**bserved: Has anyone observed you stop breathing during sleep? | |
| **P**ressure: Do you have high blood pressure? | |
| **B**MI: Is your BMI >35? | |
| **A**ge: Are you >50 years old? | |
| **N**eck: Is your neck circumference >40 cm? | |
| **G**ender: Are you male? | |

**Scoring:**
- 0-2: Low risk
- 3-4: Intermediate risk (enhanced monitoring for Protocol 3)
- 5-8: High risk (strongly consider Protocol 1-2 instead; if Protocol 3 mandatory, maximal monitoring)

### Appendix C: Apfel PONV Risk Score

**Risk Factors (1 point each):**
- Female gender
- Non-smoker
- History of PONV or motion sickness
- Postoperative opioids

**Scoring:**
- 0: PONV risk ~10%
- 1: PONV risk ~20%
- 2: PONV risk ~40%
- 3: PONV risk ~60%
- 4: PONV risk ~80%

**Protocol 3 Note:** ALL Protocol 3 patients get +1 point for opioids, so minimum Apfel score is 1.

### Appendix D: Modified Aldrete Score

**Discharge Readiness Assessment:**

| Category | 2 points | 1 point | 0 points |
|----------|----------|---------|----------|
| **Activity** | Moves 4 extremities | Moves 2 extremities | No movement |
| **Respiration** | Deep breathing, coughing | Dyspnea, shallow | Apnea |
| **Circulation** | BP ±20 mmHg baseline | BP ±20-50 mmHg | BP ±>50 mmHg |
| **Consciousness** | Fully awake | Arousable | Not responding |
| **SpO₂** | >92% room air | >90% with O₂ | <90% with O₂ |

**Total ≥9 required for discharge** (plus meeting other institutional criteria)

---

## Version History

**Version 2.0 — December 2025**
- Complete clinical validation and safety framework
- Enhanced safety protocols matching rTKA Protocol 3 rigor:
  - Opioid minimization principles ("avoid late stacking")
  - Naloxone protocols (preparation, dosing, indication)
  - Enhanced PACU monitoring requirements
  - Escalation criteria to monitored bed
- Phenotype-specific dosing throughout (elderly, OSA, chronic opioid, OUD)
- Special populations sections comprehensive
- Expected outcomes quantified with comparison to Protocols 1-2
- Protocol positioning clear (THIRD-LINE, reserved for specific indications)
- Troubleshooting scenarios (respiratory depression, refractory PONV)
- Quality metrics and continuous improvement framework
- Evidence base and references updated
- Educational disclaimer matching Protocols 1-2

**Version 1.0 — December 2025**
- Initial protocol development (incomplete safety framework)

---

## Author and License

**Author:** Collin B. George, BS  
**Project Type:** Educational pre-medical protocol framework  
**Status:** Not validated for clinical use; requires institutional review

**License:** Creative Commons Attribution 4.0 International (CC BY 4.0)

**Acknowledgment:**  
This protocol synthesizes published literature on opioid-based anesthesia, PONV management, respiratory depression monitoring, and opioid safety. All clinical decisions require attending anesthesiologist judgment and patient-specific assessment.

**Important Note:**  
This educational framework demonstrates understanding of opioid safety principles and comprehensive perioperative management. Protocol 3 represents a traditional opioid-inclusive approach with modern safety enhancements, positioned as third-line option when opioid-sparing strategies (Protocols 1-2) are not appropriate.

---

**End of Protocol 3** — *Educational resource only. Clinical implementation requires institutional governance review, attending validation, and integration with local policies and pharmacy formularies.*




